United Therapeutics Corporation (UTHR)
Market Cap | 17.39B |
Revenue (ttm) | 3.08B |
Net Income (ttm) | 1.24B |
Shares Out | 45.23M |
EPS (ttm) | 25.63 |
PE Ratio | 15.00 |
Forward PE | 13.67 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 393,810 |
Open | 395.60 |
Previous Close | 391.45 |
Day's Range | 379.39 - 396.54 |
52-Week Range | 266.98 - 436.95 |
Beta | 0.62 |
Analysts | Strong Buy |
Price Target | 424.43 (+10.38%) |
Earnings Date | Oct 29, 2025 |
About UTHR
United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitr... [Read more]
Financial Performance
In 2024, United Therapeutics's revenue was $2.88 billion, an increase of 23.63% compared to the previous year's $2.33 billion. Earnings were $1.20 billion, an increase of 21.35%.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for UTHR stock is "Strong Buy." The 12-month stock price target is $424.43, which is an increase of 10.38% from the latest price.
News

United Therapeutics: Is UTHR Stock Still A Buy At $400?
United Therapeutics' stock (NASDAQ: UTHR) surged 33% on September 2nd after the company announced positive late-stage clinical trial results for Tyvaso (treprostinil) Inhalation Solution in idiopathic...

Why Is United Therapeutics Stock Rallying On Tuesday?
United Therapeutics Corporation UTHR released data on Tuesday from its TETON-2 study evaluating the use of nebulized Tyvaso (treprostinil) Inhalation Solution for idiopathic pulmonary fibrosis (IPF).

United Therapeutics surges as Tyvaso succeeds in IPF trial: should you invest?
Shares of United Therapeutics jumped nearly 40% on Tuesday's opening trade after the company reported its inhaled lung therapy Tyvaso met the main goal in a late-stage study for idiopathic pulmonary f...

United Therapeutics shares surge on successful late-stage lung disease study
Shares of United Therapeutics surged over 42% in premarket trading on Tuesday after its lung disease treatment, treprostinil, met the main goal in a late stage study.

United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary Fibrosis
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that its TETON-2 study evaluating the ...

United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O...

United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous Year
United Therapeutics Corporation remains a Buy as it robustly defends its PAH franchise, counters competitive threats, and posts strong Q2 results with double-digit growth. Upcoming TETON-2 data for Ty...

United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase Program
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced that it will enter today into two Accelerate...

United Therapeutics Corporation (UTHR) Q2 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q2 2025 Earnings Conference Call July 30, 2025 9:00 AM ET Company Participants C.Q. Deng - Corporate Participant Dewey Steadman - Head of Investor Relati...

United Therapeutics Corporation Reports Record Second Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quart...

United Therapeutics Corporation to Report Second Quarter 2025 Financial Results Before Market Open on Wednesday, July 30, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2025 financial results before ...

United Therapeutics and Intermountain Health Announce the First Patient Treated With External Liver Support Using a Bioengineered Liver
EDEN PRAIRIE, Minn. & MURRAY, Utah--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and Intermountain Health, one of the nation's top health systems and ...

United Therapeutics Corporation Concludes Enrollment of the ADVANCE OUTCOMES Study of Ralinepag for the Treatment of Pulmonary Arterial Hypertension
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced the conclusion of enrollment of the phase 3 ...

United Therapeutics: Tanking On Rival's PAH Data - I'd Consider Buying Stock
United Therapeutics Corporation stock was down substantially yesterday as rival Insmed's PAH data blew the market away. Insmed's treprostinil based product seemingly edged United's Tyvaso on key measu...

United Therapeutics Corporation (UTHR) Q1 2025 Earnings Call Transcript
United Therapeutics Corporation (NASDAQ:UTHR) Q1 2025 Earnings Conference Call April 30, 2025 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairpers...

United Therapeutics Corporation Reports First Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the American Thoracic Society 2025 International Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that recent research across its commer...

United Therapeutics Corporation to Feature Clinical Data Across its Commercial and Development Portfolio at the International Society for Heart and Lung Transplantation 45th Annual Meeting and Scientific Sessions
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that ten posters and presentations acr...

United Therapeutics: Don't Fear The Patent Expiration Too Much
United Therapeutics is rated as a BUY due to high financial growth, positive long-term outlook, and current undervaluation despite patent expiration concerns. The company's revenue is heavily reliant ...

United Therapeutics Corporation to Present at the Leerink Partners Global Healthcare Conference 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that James Edgemond, Chief Financial O...

United Therapeutics Corporation (UTHR) Q4 2024 Earnings Call Transcript
Start Time: 09:00 January 1, 0000 9:31 AM ET United Therapeutics Corporation (NASDAQ:UTHR) Q4 2024 Earnings Conference Call February 26, 2025, 09:00 AM ET Company Participants Martine Rothblatt - Cha...

United Therapeutics Corporation Reports Fourth Quarter and Full Year 2024 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ...

United Therapeutics: A Unique Business With High Margins And Expansion Potential
United Therapeutics is highly undervalued with a P/E of 16x and EV/EBITDA of 8.64x, compared to sector medians of 28x and 15.15x, respectively. The company shows strong revenue growth, driven by Tyvas...

United Therapeutics Corporation to Present at the TD Cowen 45th Annual Health Care Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that Michael Benkowitz, President and ...

United Therapeutics Corporation to Report Fourth Quarter and Full Year 2024 Financial Results Before the Market Opens on Wednesday, February 26, 2025
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its fourth quarter and full year 2024 financial r...